Guardant Health Profile



Odds of Distress

Check how we calculate scores
Equity ratings for Guardant Health are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting July 25, 2019 and ending today October 23, 2019. Click here to learn more.
Earning Report: November 18, 2019   Follow

Guardant Health Profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in USA and is traded on BATS Exchange. It employs 454 people. more
Guardant Health Fama & French Healthcare
Fama & French Classification
Guardant Health SEC Filings
Guardant Health SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGuardant Health
CEO, DirectorHelmy EltoukhyView All
Thematic Classification
Currently Active Investing Idea
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Diagnostics & Research
InstrumentUSA Stock View All
LocationCalifornia U.S.A
Business Address505 Penobscot Drive
ExchangeBATS Exchange
IndustryDiagnostics & Research
Phone855 698 8887
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestSeptember 30, 2019
Guardant Health (GH) is traded on BATS Exchange in USA. It is located in 505 Penobscot Drive and employs 454 people. Guardant Health is listed under Healthcare category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with market capitalization of 6.1 B. Guardant Health is active under Healthcare sector as part of Diagnostics & Research industry. The entity has 92.97 M outstanding shares of which 3.38 M shares are currently sold short in the market by investors with about 2.15 days to cover all shorted shares. The company reports about 545.63 M in cash with (66.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.87.
Check Guardant Health Probability Of Bankruptcy

Ownership Allocation (%)

Guardant Health Target Price Odds Analysis

Odds Below 62.78HorizonTargetOdds Above 62.78
18.57%30 days 62.78 81.37%
Based on normal probability distribution, the odds of Guardant Health to move above current price in 30 days from now is about 81.37 (This Guardant Health probability density function shows the probability of Guardant Health Stock to fall within a particular range of prices over 30 days) .

Guardant Health Top Holders

Guardant Health Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Rhenman Partners Asset Management AbCommon Shares35 K2.2 M
Simplex Trading LlcPut Options315M
Simplex Trading LlcCall Options2511.6 M
Scott Selber IncCommon Shares20 K1.3 M
View Guardant Health Diagnostics

Guardant Health Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Guardant Health Key Fundamentals

Guardant Health Against Markets

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Guardant Health Upcoming and Recent Events

Guardant Health Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportNovember 18, 2019
Next Earnings ReportMarch 10, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndMarch 10, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018

Guardant Health Corporate Filings

Guardant Health SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Submission of Matters to a Vote of Security Holders
Other Events

Guardant Health Corporate Directors

Dipchand Nishar Independent Director
Ian Clark Lead Independent Director
Bahija Jallal Director
Please also check Risk vs Return Analysis. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.